Publications
What's New
The Gelfand lab demonstrates that apremilast reduces visceral and subcutaneous adiposity.
The Gelfand Lab investigates how to create the most effective implementation design for the CP3 Study, which aims to improve cardiovascular health in patients with psoriatic disease.
- Specialist and Patient Perspectives on Strategies to Improve Cardiovascular Disease Prevention Among Persons Living with Psoriatic Disease
- Analysis of Specialist and Patient Perspectives on Strategies to Improve Cardiovascular Disease Prevention Among Persons Living with Psoriatic Disease
The Gelfand Lab publishes the first and largest mutli-center study of the epidemiology of generalized pustular psoriasis (GPP) and palmer planter pustulosis (PPP) in the US.
- Evaluation of a Case Series of Patients With Palmoplantar Pustulosis in the United States
- Evaluation of a Case Series of Patients With Generalized Pustular Psoriasis in the United States
Selected Major Findings
The Gelfand Lab's research demonstrates that body surface area affected by psoriasis is an important predictor for major health outcomes. Check out results from the incidence health outcomes and psoriasis events (iHOPE) study:
- Psoriasis and the Risk of Diabetes: A Prospective Population Based Cohort Study
- Objective Measures of Psoriasis Severity Predict Mortality: A Prospective Population-Based Cohort Study
- Prevalence of Metabolic Syndrome in Patients with Psoriasis: A Population-Based Study in the United Kingdom
- Body Surface Area Affected by Psoriasis and the Risk for Psoriatic Arthritis: A Prospective Population-Based Cohort Study
- Effect of Psoriasis Severity on Hypertension Control: A Population-Based Study in the United Kingdom
- Psoriasis Severity and the Prevalence of Major Medical Comorbidity: A Population-Based Study
- Increased Prevalence of HCV and Hepatic Decompensation in Adults with Psoriasis: A Population-Based Study in the United Kingdom
The Gelfand Lab's research demonstrates an increased cardiovascular risk and an increased risk of diabetes, kidney disease and mortality in patients with psoriasis independent of traditional risk factors:
- The Risk of Myocardial Infarction in Patients with Psoriasis
- Risk of Moderate to Advanced Kidney Disease in Patients with Psoriasis: Population Based Cohort Study
- Risk of Major Cardiovascular Events in Patients with Psoriatic Arthritis, Psoriasis and Rheumatoid Arthritis
- The Risk of Stroke in Patients with Psoriasis
- Increased Risk of Diabetes Mellitus and Likelihood of Receiving Diabetes Mellitus Treatment in Patients with Psoriasis
- Patients with Severe Psoriasis are at Increased Risk of Cardiovascular Mortality: Cohort Study Using the General Practice Research Database
The Gelfand Lab determines the effect of psoriasis treatment on aortic vascular inflammation and biomarkers of inflammation, lipid and glucose metabolism:
- Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial.
- A Phase IV, Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U Trial)
- A Randomized Placebo Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate to Severe Plaque Psoriasis (VIP-S)
The Gelfand Lab demonstrates the validity of electronic health data for studying psoriasis and psoriatic arthritis:
- Prevalence and Treatment of Psoriasis in the United Kingdom: A Population-Based Study
- Prevalence and Treatment Patterns of Psoriatic Arthritis in the UK
- Validity of The Health Improvement Network (THIN) for the Study of Psoriasis
- Validity of Psoriatic Arthritis and Capture of Disease Modifying Antirheumatic Drugs in The Health Improvement Network
The Gelfand Lab's contributions to COVID research:
- Ultraviolet Germicidal Irradiation: Possible Method for Respirator Disinfection to Facilitate Reuse During the COVID-19 Pandemic
- National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1
- National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 2-Advances in Psoriatic Disease Management, COVID-19 Vaccines, and COVID-19 Treatments
- The Risk of Respiratory Tract Infections and Symptoms in Psoriasis Patients Treated with Interleukin 17 Pathway-Inhibiting Biologics: A Meta-Estimate of Pivotal Trials Relevant to Decision Making During the COVID-19 Pandemic
- Effect of Anti-Tumor Necrosis Factor Therapy on the Risk of Respiratory Tract Infections and Related Symptoms in Patients with Related Symptoms in Patients with Psoriasis-A Meta-Estimate of Pivotal Phase 3 Trials Relevant to Decision Making During the COVID-19 Pandemic
- The Risk of Respiratory Tract Infections in Patients with Psoriasis Treated with Interleukin 23 Pathway-Inhibiting Biologics: A Meta-Estimate of Pivotal Trials Relevant to Decision Making During the COVID-19 Pandemic
- Clinical Research after COVID-19: Embracing a New Normal
Educational Articles from Dr. Gelfand's Lab:
- Engaging the Patient's Perspective in Clinical Trials Research
- Research Techniques Made Simple: Pharmacoepidemiology Research Methods in Dermatology
- Psoriasis and Cardiovascular Risk: Strength in Numbers
- Psoriasis and Cardiovascular Risk: Strength in Numbers Part 2
- Psoriasis and Cardiovascular Risk: Strength in Numbers Part 3
- Psoriasis and Comorbid Diseases: Implications for Management